Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Pharmaceutical Contract Sales Outsourcing Market, By Service
7.1. Pharmaceutical Contract Sales Outsourcing Market, by Service, 2021-2030
7.1.1. Personal Promotion
7.1.1.1. Market Revenue and Forecast (2016-2030)
7.1.2. Non-personal Promotion
7.1.2.1. Market Revenue and Forecast (2016-2030)
7.1.3. Others (Field Management/Reporting and Sales Training)
7.1.3.1. Market Revenue and Forecast (2016-2030)
Chapter 8. Global Pharmaceutical Contract Sales Outsourcing Market, By Therapeutic Area
8.1. Pharmaceutical Contract Sales Outsourcing Market, by Therapeutic Area, 2021-2030
8.1.1. Cardiovascular Disorders
8.1.1.1. Market Revenue and Forecast (2016-2030)
8.1.2. Oncology
8.1.2.1. Market Revenue and Forecast (2016-2030)
8.1.3. Metabolic Disorders
8.1.3.1. Market Revenue and Forecast (2016-2030)
8.1.4. Neurology
8.1.5. Market Revenue and Forecast (2016-2030)
8.1.6. Orthopedic Diseases
8.1.6.1. Market Revenue and Forecast (2016-2030)
8.1.7. Infectious Diseases
8.1.7.1. Market Revenue and Forecast (2016-2030)
8.1.8. Others
8.1.8.1. Market Revenue and Forecast (2016-2030)
Chapter 9. Global Pharmaceutical Contract Sales Outsourcing Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Service (2016-2030)
9.1.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Service (2016-2030)
9.1.3.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Service (2016-2030)
9.1.4.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Service (2016-2030)
9.2.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Service (2016-2030)
9.2.3.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Service (2016-2030)
9.2.4.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Service (2016-2030)
9.2.5.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Service (2016-2030)
9.2.6.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Service (2016-2030)
9.3.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Service (2016-2030)
9.3.3.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Service (2016-2030)
9.3.4.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Service (2016-2030)
9.3.5.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Service (2016-2030)
9.3.6.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Service (2016-2030)
9.4.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Service (2016-2030)
9.4.3.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Service (2016-2030)
9.4.4.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Service (2016-2030)
9.4.5.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Service (2016-2030)
9.4.6.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Service (2016-2030)
9.5.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Service (2016-2030)
9.5.3.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Service (2016-2030)
9.5.4.2. Market Revenue and Forecast, by Therapeutic Area (2016-2030)
Chapter 10. Company Profiles
10.1. Ashfield (UDG Healthcare plc)
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. inVentiv Health
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Inc. (Syneos Health)
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. IQVIA
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Granard Pharmaceutical Sales & Marketing
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Vanguard Pharma Inc.
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. GTS Solution
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. EVERSANA
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. MaBiCo
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. MaBiCo
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms